


Price	<del>N</del> 2.15
FVE	₩2.9
52-week range	₩1.40 <b>-</b> 2.90
Market Cap. (₩'bn)	63,165
1-month Avg. Vol	12,858,613
Curr. PB	0.27x

#### FIDELITY:NL - Share Price Trend



### Emmanuel.Adeleke Emmanuel.Adeleke@arm.com.ng

# Fidelity Bank Plc. (FIDELITYBK.NL)

### Initial View

## Full year performance ends on a good note

- Fidelity Bank Plc reported EPS growth of 28.5% YoY to №1.02/share, coming slightly above our estimate of №0.91/share. The deviation stemmed from a net-write back of №2.1 billion relative to our forecast of №1.6 billion in loan-loss provisioning. We would keep an eye on this line item after the results have been audited and approved by the CBN.
- Key drivers of the result were strong growth in interest income and lower provisioning, both of which masked a decline in Non-interest revenue and sharp increase in interest expense. To start with, growth in interest income largely reflected increase in interest income on customer loans as the bank expanded its loan book significantly by 33% YoY to №1.1 trillion. Despite a 20.3% YoY increase in interest expense − a fallout of higher interest expense on deposits, Net interest income still printed higher (+18.1% YoY to №82.2 billion), thanks to the strong growth in interest income. Elsewhere, a net-write back of №2.1 billion was recorded compared to an impairment charge of №4.2 billion in 2018. Overall, the growth in NII and net-write back neutered a moderation in NIR (-9.9% YoY) as well as higher OPEX (+11.8% YoY).
- Quarterly breakdown revealed a similar decent performance reflective of improved NIMs and a net-write-back of \$\frac{\text{N}}{2}.0\$ billion compared to a loan-loss provision of \$\frac{\text{N}}{6}30\$ million in the previous quarter. On the former, NIMs (+20 bps QoQ) improved following a faster decline in cost of fund (-130 bps QoQ). Given that CASA mix remained unchanged over the quarter, we believe the decline in funding cost is not unrelated to the lower rate environment in Q4 19. Overall, PBT came in higher by 17.9% QoQ while PAT recorded a slow growth of 2.9% QoQ owing to a higher effective tax rate (Q4 19: 14.6%, Q3 19: 2.2%).
- While we await audited results and management's presentation, we note the key risks to consider over 2020 includes: possibility of higher loan-loss provisioning given the significant loan growth over 2019 which exceeded the industry average. On the other hand, we expect funding cost to take a breather owing to a lower rate environment. In addition, NIR declined 9.8% YoY due to a high base of FX gains in 2018. Hence, we expect a normalization and thus, expect to see some growth in NIR over the year.

• We will give update to our forecasts for 2020 upon release of the audited result. Our last communicated FVE of №2.9, translates to a **BUY** recommendation on our rating scale. FIDELITY trades at a current P/B of 0.27x, a discount to 1-year average of 0.38x.

# **Summary of Results**

N'million	FY 2019	FY 2018	YoY (pps)	Q4 19	Q3 19	QoQ
Gross Earnings	217,306	188,873	15.05%	56,251	57,400	-2.00%
Net Interest Income	82,158	69,587	18.07%	23,912	21,347	12.02%
Non-Interest Revenue	28,719	31,845	-9.82%	6,222	6,944	-10.40%
Operating Expenses	(80,633)	(72,128)	11.79%	(22,755)	(19,709)	15.45%
Impairment	2,132	(4,215)	-150.58%	1,994	(630)	-416.51%
РВТ	32,376	25,089	29.04%	9,373	7,952	17.87%
PAT	29,462	22,926	28.51%	8,001	7,776	2.89%
EPS	1.02	0.79	28.51%	0.28	0.27	2.89%
N'million	FY 2019	FY 2018	YoY (pps)		Q3 19	QoQ
Loans	1,127,749	849,880	32.70%		1,074,096	5.00%
Total Assets	2,116,295	1,719,883	23.05%		1,970,620	7.39%
Deposits	1,225,214	979,413	25.10%		1,116,416	9.75%
Total Liabilities	1,882,590	1,525,467	23.41%		1,748,894	7.64%
Net Assets	233,705	194,416	20.21%		221,726	5.40%
BVPS	8.07	6.71	20.21%		7.66	5.40%
	FY 2019	FY 2018	change (pps)	Q4 19	Q3 19	change (pps)
Assets Yields	12.00%	12.22%	-0.22%	9.43%	10.49%	-1.06%
WACF	5.90%	6.22%	-0.32%	5.46%	6.78%	-1.33%
Net Interest Margin	5.38%	5.53%	-0.16%	5.37%	5.16%	0.20%
Cost-Income Ratio	72.72%	71.11%	1.61%	75.51%	69.67%	5.85%
Cost of Risk	-0.19%	0.50%	-0.69%	-0.71%	0.23%	-0.94%
ROE	12.61%	11.79%	0.81%	17.57%	16.68%	0.89%

#### **ARM ratings and recommendations**

ARM now employs a two-tier rating system which is based on systemic importance of the security under review and the deviation of our target price for the stock from current market price. We characterize systemic importance as a function of a stock's ranking among the group of top 20 stocks by NSE market capitalization over a trailing 6-month period (minimum) to the review date. We adopt a 5-point rating system for this category of stocks and a 3-point rating system for stocks outside this group. The choice of top 20 stocks arises from the consideration that this group of stocks constitutes >75% of overall market capitalization and stocks outside this group are generally less liquid and individually account for <<1% of market capitalization. For stocks in both categories, the basis for ratings subject to target price deviation is outlined below:

TOP 20		NON-TOP 20	
Rating	Deviation	Rating	Deviation
STRONG BUY	>20%	BUY	>20%
OVERWEIGHT	10% — 20 %	NEUTRAL	5% — 20%
NEUTRAL	0% — 10%	SELL	< 5%
UNDERWEIGHT	-5% — 0%		
SELL	<-5%		

RECOMMENDATION KEY			
Rating	Recommendation		
BUY	Accumulate security to a substantial extent constrained only by portfolio diversification considerations		
OVERWEIGHT	Accumulate security to an extent moderated by cognizance of its benchmark weight		
NEUTRAL	Maintain status quo for security with respect to current holding—i.e. keep if already holding and don't buy otherwise—subject to reas portfolio constraints		
UNDERWEIGHT	Minimize exposure to security taking cognizance of its index weighting		
SELL	Sell-off security completely from portfolio		

Copyright © 2020 ARM Securities Limited ("ARMS").

All rights reserved. Unauthorised use, reproduction, distribution, or disclosure of this document is strictly prohibited.

This material has been issued by ARM Securities Limited, a member of the Asset and Resource Management ("ARM") Group, and a Company regulated by the Nigerian Securities & Exchange Commission. The analyst(s) primarily responsible for preparing this research report, in whole or in part, certifies that with respect to each security or issuer covered; all of the views expressed accurately reflect his/her personal views about the subject securities and issuers and no part of his/her compensation was, is, or will be, directly or indirectly, related to the inclusion of specific recommendations or views in the report.

This research report is based on information from sources that ARMS and its analysts believe to be reliable. Neither ARMS nor any of its research analysts, nor any member of the ARM Group, gives any representation or warranty, express or implied, or undertaking of any kind or assumes responsibility or liability of any kind with respect to the accuracy or completeness of the information set out in this report or any third party's use (or the results of such use) of such information. This report is provided solely for informational purposes and is not to be construed as providing advice, recommendations, or endorsements of any kind whatsoever. The investments and strategies discussed here may not be suitable for all investors; counsel of investment advisor should be obtained with regard to such investments and or strategies. This research report is not a replacement for advice from an accountant, lawyer, personal finance advisor or other category of investment advisor. The investments discussed in this report may oscillate in price or value. Opinions and information provided are made as of the date of the report issue and are subject to change without notice. This research report is not intended as an offer or solicitation for the purchase or sale of any financial instrument. Reference herein to any specific security or financial instrument does not necessarily constitute or imply its endorsement or recommendation by ARMS, its directors, officers, employees or designated agents. Members of ARM may act as broker, advisor or lender, or make a market in any investments or issuers referenced in this report. Further information on any of the securities discussed herein may be obtained upon request to ARMS. By accepting this document, you agree to be bound by the foregoing limitations.